Abstract: An imidazole derivative represented by formula (I): wherein Q is: A is hydrogen, halogen, or a substituted or unsubstituted C1-4 alkyl group; E is independently selected from a C1-6 alkyl group; R2 and R3 are independently selected from C1-6 alkyls; X1 and X2 are independently selected from O and S; Y is selected from a substituted or unsubstituted arylene group and a substituted or unsubstituted divalent 5- or 6-membered monocyclic or 8- to 10-membered condensed heterocyclic group; Z is —CON(—Ra)—, —CO—, —OOO—, —NRa—C(?NH)NRb—, —NRa—C(?N—CN)NRb—, —N(—Ra)COO—, —C(?NH)—, —SO2—, —SO2N(—Ra)—, —SO2NR1—, —N(—Ra)CO—, —N(—Ra)CON(—Rb)—, —N(COR1)CO—, —N(—Ra)SO2—, —N(SO2R1)SO2—, —N(—Ra)— or —N(—Ra)SO2N(—Rb)—; R1 is independently a hydrogen atom, a hydroxyl group, or substituted or unsubstituted group selected from C1-6 alkyl group, heterocyclic group, aryl group, C3-8 cycloalkyl group and C3-8 cycloalkenyl group; or salt or prodrug thereof.

Abstract: An object of the present invention is to provide a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint diseases. There is provided a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint diseases, wherein methotrexate is conjugated with a carboxyl group of hyaluronic acid through a linker containing a peptide chain consisting of 1 to 8 amino acids.

Abstract: According to the present invention, a compound represented by formula (I): wherein Q is: A is a hydrogen atom, a halogen atom, —ORa or a C1-4 alkyl group which may be substituted by one or more halogen atoms; E is independently selected from a C1-6 alkyl group; m is selected from integers from 0 to 3; R2 and R3 are independently selected from a C1-6 alkyl group; X1 and X2 are independently selected from O and S; Y is selected from an arylene group and a divalent 5- or 6-membered monocyclic or 8- to 10-membered condensed heterocyclic group, wherein the arylene group and the heterocyclic group may be substituted by 1 to 3 substituents independently selected from E1; E1 is independently selected from a hydroxyl group, a halogen atom, a C1-4 alkyl group, a cyano group, a C1-4 alkoky group, a carbamoyl group, a C1-4 alkylcarbamoyl group, a di(C1-4 alkyl)carbamoyl group, an amino group, a C1-4 alkylamino group, a di(C1-4 alkylamino group, a sulfamoyl group, a C1-4 alkylsulfamoyl group and a di(C1-4 alkyl)su

Abstract: The present invention provides novel ?-amino acid derivatives of formula (1): (wherein, R1, R2, R3, R4, X and Y are as defined in the claims) or pharmaceutically acceptable salts, prodrugs or solvates thereof. The derivatives of formula (1) have ?ARK1 inhibitory activity and are useful for preventing or treating heart failure. Moreover, the derivatives of formula (1) also have antitumor activity, particularly dual inhibitory activity on Aurora kinase and CDK, and are useful for cell proliferative diseases such as cancer.

Abstract: An object of the present invention is to provide a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint disorders. There is provided a hyaluronic acid-methotrexate conjugate useful for the treatment of joint disorders, wherein methotrexate is conjugated with a hydroxy group of hyaluronic acid through a linker containing a peptide chain consisting of 1 to 8 amino acids, and the linker is conjugated with the hyaluronic acid through a carbamate group.

Abstract: The present invention provides a compound represented by formula (I): wherein n is an integer selected from 1 to 20, Q is A is cyano or the like; B is hydrogen, halogen, or the like; X1 and X2 are each independently selected from O and S; E is a C1-4 alkyl group; and R1, R2, R3 and R4 are each independently selected from a hydrogen atom and a C1-C6 alkyl group, and a drug, a pharmaceutical composition containing the compound, and the like.

Abstract: The present invention provides novel ?-amino acid derivatives of formula (1): (wherein, R1, R2, R3, R4, X and Y are as defined in the claims) or pharmaceutically acceptable salts, prodrugs or solvates thereof. The derivatives of formula (1) have ?ARK1 inhibitory activity and are useful for preventing or treating heart failure. Moreover, the derivatives of formula (1) also have antitumor activity, particularly dual inhibitory activity on Aurora kinase and CDK, and are useful for cell proliferative diseases such as cancer.

Abstract: An object of the present invention is to provide a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint disorders. There is provided a hyaluronic acid-methotrexate conjugate useful for the treatment of joint disorders, wherein methotrexate is conjugated with a hydroxy group of hyaluronic acid through a linker containing a peptide chain consisting of 1 to 8 amino acids, and the linker is conjugated with the hyaluronic acid through a carbamate group.

Abstract: The present invention provides a compound represented by formula (I): wherein n is an integer selected from 1 to 20, Q is A is cyano or the like; B is hydrogen, halogen, or the like; X1 and X2 are each independently selected from O and S; E is a C1-4 alkyl group; and R1, R2, R3 and R4 are each independently selected from a hydrogen atom and a C1-C6 alkyl group, and a drug, a pharmaceutical composition containing the compound, and the like.

Abstract: The present invention provides a compound represented by formula (I): [Formula 1] wherein n is an integer selected from 1 to 20, and R1 and R2, which may be the same or different, each represent a hydrogen atom, or a linear or branched C1-C6 alkyl group, or a salt, a prodrug or a solvate thereof, as well as a drug, a pharmaceutical composition containing the compound, and the like.

Abstract: An object of the present invention is to provide a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint diseases. There is provided a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint diseases, wherein methotrexate is conjugated with a carboxyl group of hyaluronic acid through a linker containing a peptide chain consisting of 1 to 8 amino acids.

Abstract: A ceramic heater which includes: a cylindrical substrate including an insulator; a resistor provided in one end side of the substrate; a pair of lead parts provided in the substrate, connected to the resistor and extending to an opposite end side of the substrate; and a pair of electrode parts exposed to a surface at an opposite end side of the substrate and connected respectively to the lead parts. Both lead parts are made of the same material as both electrode parts. An axial cross-sectional area of the electrode part is equal to or larger than a cross-sectional area of the lead part in a direction perpendicular to an axis of the ceramic heater.

Abstract: The present invention provides a compound represented by formula (I): wherein n is an integer selected from 1 to 20, and R1 and R2, which may be the same or different, each represent a hydrogen atom, or a linear or branched C1-C6 alkyl group, or a salt, a prodrug or a solvate thereof, as well as a drug, a pharmaceutical composition containing the compound, and the like.

Abstract: A compound of Formula (1): ? wherein R1 represents an amidinophenyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a carbamoylalkyl group, etc.; R4 represents a hydrogen atom, etc.; R5 represents a benzyl group, etc.; R6 represents a hydrogen atom, etc.; and R7 represents an alkylsulfonyl group, etc. A crystal of a complex between factor VIIa/human soluble tissue factor and a low-molecular weight reversible factor VIIa inhibitor. A medium carrying a part or all of structure coordinate data of a complex between human factor VIIa/human soluble tissue factor and a low-molecular weight reversible factor VIIa inhibitor, obtainable by X-ray crystal structure analysis of the crystal. A method for computationally designing a low-molecular weight reversible factor VIIa inhibitor using the coordinate data.

Abstract: A ceramic heater which includes: a cylindrical substrate including an insulator; a resistor provided in one end side of the substrate; a pair of lead parts provided in the substrate, connected to the resistor and extending to an opposite end side of the substrate; and a pair of electrode parts exposed to a surface at an opposite end side of the substrate and connected respectively to the lead parts. Both lead parts are made of the same material as both electrode parts. An axial cross-sectional area of the electrode part is equal to or larger than a cross-sectional area of the lead part in a direction perpendicular to an axis of the ceramic heater.

Abstract: An instrument panel of a vehicle is attached on a reinforce which is fixed on a part of a vehicle body. A first connector is provided on at least one of both longitudinal end portions of the reinforce. The first connector is electrically connected to electric equipments provided with the instrument panel. A second connector is provided on the vehicle body such that electric connection is effected with the first connectors when the reinforce is fixed on the vehicle body.

Abstract: A compound of Formula (1): 1

Abstract: A ceramic heater 2 is arranged in a metallic cylinder member 3 by forming a convergent taper portion 2t at the leading end 2a of the ceramic heater 2 and by positioning the leading end 3a of the metallic cylinder member 3 on the leading end side of a taper starting point P1 of the taper portion 2t. Solder is applied in the clearance between the inner circumference 3d of the metallic cylinder member 3 and the outer circumference 2b of the heater 2. An applied solder layer 10 is also formed on the leading end side of the taper starting point P1 of the taper portion 2t. The thick solder layer 10 present on the leading end side prevents a cut or broken off portion of the ceramic heater from separating or sliding out.

Abstract: A ceramic heater 1 includes a rodlike heater body 2 configured such that a ceramic resistor 10 is embedded in a ceramic substrate 13. The ceramic resistor 10 includes a front end part 11a and two large-diameter rodlike portions Ld. The large-diameter rodlike portions Ld form passages for supplying electricity to the front end part 11a, extend rearward along a direction of an axis O of the heater body 2, and have an electricity-supply sectional area greater than that of the front end part 11a. The large-diameter rodlike portions Ld each have a connection end part connected to the front end part 11a. The connection end part is formed of a first electrically conductive ceramic and constitutes a first resistor portion 11. The remaining portion of each of the large-diameter rodlike portions Ld is formed of a second electrically conductive ceramic having an electrical resistivity lower than that of the first electrically conductive ceramic and constitutes a second resistor portion 12.

Abstract: An electrical equipment (component) for a vehicle is separated into an exterior appearance member and an interior control member including a drive circuit for the electrical equipment (component). The exterior appearance member is provided on a dash panel. The interior control member is provided on a reinforcement. The dash panel and the reinforcement are then integrated.